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Abstract
Background: The establishment of a tree shrew model for systemic lupus erythematosus (SLE) provides a new
method to evaluate the pathogenesis of autoimmune diseases.
Methods: Eighty tree shrews were randomly divided into four groups receiving either an intraperitoneal injection
of pristane, lipopolysaccharide (LPS), or pristane and LPS, or no injection. Three weeks after injection, the SLE model
tree shrews were divided into the model group and the treatment group. Tree shrews in the treatment group and
the normal control group were infused with umbilical cord mesenchymal stem cells (UC-MSCs). The cells were
labeled with DiR. Two weeks after transplantation, three groups of tree shrews were analyzed for urine protein,
serum antinuclear antibodies and antiphospholipid, and inflammatory cytokine antibody microarray detection. The
heart, liver, spleen, lung, and kidney were collected from the three groups and subjected to hematoxylin and eosin
(HE) staining and detection of renal immune complex deposition.
Results: HE staining indicated pathology in the model group. Red fluorescence revealed immune complex deposition
in the kidneys from the model group.
Conclusions: The combined intraperitoneal injection of pristane and LPS is the best way to induce SLE
pathological changes. The pathological changes improved after UC-MSC treatment.
Keywords: Systemic lupus erythematosus, Tree shrews, Animal models, Umbilical cord mesenchymal stem cells,
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Abbreviations: BM-MSC, Bone marrow mesenchymal stem cell; EAE, Autoimmune encephalomyelitis;
IL, Interleukin; LPS, Lipopolysaccharide; MSC, Mesenchymal stem cell; OD, Optical density; RA, Rheumatoid arthritis;
SLE, Systemic lupus erythematosus; Th17, T-helper 17; TNFα, tumor necrosis factor alpha; UC-MSC, Umbilical cord
mesenchymal stem cell
Background
Systemic lupus erythematosus (SLE) is an autoimmune
disease of unknown etiology. A variety of autoanti-
bodies and immune complexes appear in the serum of
SLE patients, along with severe glomerulonephritis [1].
Effective treatments for SLE are presently lacking. The
establishment of an appropriate animal model is an
essential research tool to investigate drug treatment
efficacy during the pathogenesis of the disease. Tree
shrews are climbing animals between insectivores and
primates. Evolutionarily closer to primates than ro-
dents, tree shrews are being considered as an alterna-
tive to primates for study. Because tree shrews are
small in size and cheap in price compared with pri-
mates, we chose this model over primates. Tree shrews
were found to have genetic characteristics close to
those of primates, which laid the foundation for re-
search into clinical disease mechanisms and the devel-
opment of new drugs.
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The kidney is the most affected organ in mouse and
human SLE. Lupus nephritis results in immune complex
deposition in different parts of the glomeruli [2]. When
lupus nephritis cannot be well controlled, glomerulo-
nephritis will eventually develop and advance to renal
failure [3]. Generally, SLE therapy – particularly cyclo-
phosphamide therapy – can control most lupus nephritis
well, but not all cases can be controlled. Better under-
standing of the pathogenesis of the disease is thus very
important to improve the therapeutic effect of SLE. SLE
has a complex etiology, and the exact mechanism of this
autoimmune disease has not been elucidated. However,
SLE is generally agreed to be due to a genetic predispos-
ition and appears in response to environmental factors
and infections. Specifically, a susceptibility gene regu-
lates the pathogenesis of SLE, and lymphocytes and cy-
tokines participate in abnormal immune responses,
which significantly increase autoantibodies and damage
to the body.
Mesenchymal stem cells (MSCs) are a class of cells
found in the bone marrow, fat, muscle, and other tissues.
These cells are multipotent and have the immunomodu-
latory effects of nonhematopoietic stem cells [4]. Adult
bone marrow mesenchymal stem cells (BM-MSCs)
mainly form the hematopoietic microenvironment and
regulate the growth and differentiation of hematopoietic
stem cells. In addition, MSCs can differentiate into bone,
cartilage, fat, cardiac tissue, neuronal tissue, and other
mesodermal cells. MSCs have low or no immunogenicity
[5], which decreases the probability of allogeneic trans-
plant rejection and thus constitutes safer treatment. Um-
bilical cord mesenchymal stem cells (UC-MSCs) have
the advantage of easier access than the BM-MSCs used
in the past, which has made them a clinical research
focus [6].
SLE occurs mainly in young women and is an auto-
immune disease that involves multiple organs and is
characterized by T-cell and B-cell activation. The exact
mechanism of the pathogenesis of SLE remains unclear,
but studies have confirmed that abnormal T-cell im-
munity plays an important role. This abnormal immun-
ity strongly relates to the development and prognosis
of the disease. T-helper 17 (Th17) cells are novel CD4+
effector T cells identified in recent years that may se-
crete interleukin (IL)-17, which is involved in the
innate immune and adaptive immune responses and
plays an important role in the pathogenesis of SLE [7].
Furthermore, IL-17 is involved in the innate immune
response and induces expression of inflammatory cyto-
kines IL-6 and IL-16, among others; amplifies tumor ne-
crosis factor alpha (TNFα) during inflammation; and is
involved in adaptive immune responses. Studies have
shown that Th17 cells are involved in the pathogenesis
of SLE [8], rheumatoid arthritis (RA), autoimmune
encephalomyelitis (EAE), autoimmune enteropathy,
psoriasis, and other diseases. The transplantation of UC-
MSCs reduces the levels of Th17 cells in SLE patients
[9], and a decrease in Th17 lymphocytes is likely one of
the effective mechanisms of UC-MSC transplantation in
the treatment of SLE [10].
In recent years, the incidence of autoimmune disease
has increased and SLE remains a problem. When study-
ing this topic, an animal model of SLE is one of the best
research tools, especially for the study of the genetic as-
pects of susceptibility and pathogenesis. The use of the
tree shrew model can control the impact of environmen-
tal factors on experimental animals, help to clarify the
pathogenesis of the disease, and help to identify the
pathogenic gene locus. The tree shrew model developed
in this study aims to elucidate the exact mechanism of
lupus nephritis and the mechanisms and efficacy of UC-
MSCs in the treatment of SLE.
Methods
Tree shrew UC-MSCs isolated, cultured, and identified
Full-term pregnant tree shrews were anesthetized using
intraperitoneal pentobarbital sodium (50 mg/kg body
weight) before caesarean section. The uterus was first
surgically opened to fully expose the placenta and the
fetal tree shrews, and approximately 5 cm of umbilical
cord was isolated from the fetus and placenta via sterile
laparotomy; approximately three or four umbilical cords
were isolated based on the number of fetuses. The um-
bilical cord was cleaned on a sterile bench and soaked
with double antibiotics. The umbilical cord was then cut
and placed in adherent culture flasks, in which adherent
cells were visible after 2–3 days. The medium was 20 %
fetal bovine serum in DMEM-F12 (Hyclone). The cells
were subcultured when confluent. The third passages of
tree shrew UC-MSCs were labeled with antibodies for
flow cytometry. The antibodies included CD29-FITC,
CD44-FITC, CD34-FITC, and FITC isotype controls. CD
antibodies were purchased from BD Company. Experi-
mental protocols were approved by the Experimental
Animal Ethics Committee of Kunming General Hospital
of Chengdu Military Command.
Tree shrew grouping and injection
Eighty Tupaia belangeri Chinese tree shrews that had
been domesticated by the Institute of Medical Biology,
Chinese Academy of Medical Sciences at the Tree Shrew
Germplasm Resource Center were randomly divided into
four groups of 20. The groups received one of the fol-
lowing treatments: intraperitoneal injection of 1 ml pris-
tane, intraperitoneal injection of 1 ml lipopolysaccharide
(LPS), intraperitoneal injection with pristane and LPS,
and no injection (normal controls). Pristane and LPS
were purchased from Sigma Chemical Co.; LPS was
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dissolved to 0.5 mg/ml, and the injection volume was
1 ml per tree shrew. LPS and pristane were injected once
every week for 3 weeks. After injection for 1, 2, or
3 weeks, the serum was collected and packaged in an
ELISA plate. HRP-labeled rabbit anti-monkey IgG anti-
body was used to observe serum IgG changes. Each tree
shrew serum sample was then sent to a clinical labora-
tory to detect complement C3 levels.
Quantitative PCR
Blood (0.5 ml) was collected from all tree shrews in each
group. RNA was extracted using a blood RNA extraction
kit from Baitaike according to the manufacturer’s in-
structions. Reverse transcription was carried out using
the reverse transcription kit from Thermo according to
the manufacturer’s instructions. Quantitative PCR was
carried out using Thermo quantitative PCR reagents to
detect the relative expression of IL-17 and Foxp3. The
primer sequences and product lengths are presented in
Table 1. The relative expression of IL-17 and Foxp3 was
normalized by comparison with GAPDH.
ELISA detection of tree shrew serum IgG
Because monkey secondary antibody reagents cross-
react with tree shrew IgG, we purchased an HRP-labeled
rabbit anti-monkey IgG antibody (Sigma) to detect tree
shrew serum IgG. The serum was packaged in an ELISA
plate at 4 °C overnight and then incubated with HRP-
labeled rabbit anti-monkey IgG antibody at 37 °C for
1 hour and washed three times. The chromogenic agent
TMB was used to obtain a colorimetric optical density
(OD) value at 450 nm.
Model tree shrew grouping
According to the results of quantitative PCR and serum
IgG ELISA, 10 modeled tree shrews were selected from
the pristane and LPS group. The ELISA OD of standard
model tree shrews was >2.8, more than twice the mean
OD value (1.4) of the normal control group. Quantitative
PCR showed that the relative expression of the IL-17
gene was more than twice that of the normal control
group, while the relative expression of the Foxp3 gene
was less than 0.5 that of the normal control group.
Labeling and transplantation of tree shrew UC-MSCs
Ten model tree shrews were divided into the model con-
trol group and the treatment group with five animals per
group, and five normal tree shrews were then randomly
selected as the normal control group. The UC-MSCs of
tree shrews were digested with 0.25 % trypsin, and the
digestion was terminated with complete medium con-
taining 20 % FBS. The cells were uniformly pipetted, as-
pirated into a 15 ml centrifuge tube, and counted. The
cells were labeled at a concentration of 1 × 106 cells/ml,
and 1 ml of this cell suspension was added to 5 μl of a
3 mM stock solution of DiR. The resulting mixture was
incubated at 37 °C for 10 minutes and then washed
three times with prewarmed serum-free medium (centri-
fugal rotation: 2000 rev/min, centrifugation time: 5 mi-
nutes). The labeled cells (1 × 106 cells) were injected into
the tail veins of treatment group and normal control
group animals.
ELISA detection of serum antiphospholipid and
antinuclear antibodies
Two weeks after cell transplantation, venous blood was
collected from three groups of tree shrews. The serum
was separated to detect antiphospholipid and antinuclear
antibody changes. The antiphospholipid ELISA kit was
purchased from Abcam Company and the antinuclear
antibody ELISA kit was purchased from ALPHA DIAG-
NOSTIC Company. The operating steps were followed
strictly according to kit instructions.
Three groups of tree shrews: urinary protein quantitation
Two weeks after cell transplantation, tree shrew morn-
ing urine was collected from three groups. The urinary
protein concentration was detected by the Bradford
method. The protein assay kit was purchased from
Biyuntian Company. The steps were followed in strict
accordance with the kit instructions.
Three groups of tree shrews: serum inflammatory
cytokine antibody microarray analysis
Two weeks after cell transplantation, venous blood was
collected from three groups of tree shrews. Serum was
separated to detect inflammatory cytokine antibodies by
microarray. The chips were purchased from Raybiotech
Company. The detection steps were followed strictly ac-
cording to the instructions.
HE staining and kidney Masson and PAS staining
Two weeks after cell transplantation, the heart, liver,
spleen, lung, and kidney of the normal control group,
the model control group, and the treated group were
Table 1 Primer sequences and product lengths





IL-17 TATGAGGAGCAAATGGGTCA 117 60
CAGCAAAGTAACATCCAGCCTA
Foxp3 CACTCAAGGAGGCGTTGTC 175 60
GGTGGCATAGGTGAAAGGAG
GAPDH GTTTGTGATGGGCGTGAAC 171 60
GTCTTCTGGGTGGCAGTGA
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soaked in 4 % paraformaldehyde and sent to Wuhan
Google Biotechnology Co., Ltd for hematoxylin and
eosin (HE) staining and kidney Masson and periodic
acid–Schiff (PAS) staining. The stained sections were
photographed and analyzed. From each section within
each group, three images were randomly selected and
photographed at 400× magnification for analysis. The
Image-Pro Plus6.0 software tool was used to circle each
glomerular picture. The analysis of each glomerulus
from each photograph shows the red sugar area ratio of
the total area of the glomerulus, which is the percentage
of carbohydrate area.
Detection of renal immune complex deposition
The sections were deparaffinized in xylene solution and
subjected to antigen retrieval. The sections were first in-
cubated with rabbit anti-monkey IgG antibody at 4 °C
overnight, followed by a solution of secondary antibody
(CY3; goat anti-rabbit 1:300), which covered the tissue
at room temperature in the dark for 60 minutes. DAPI-
stained nuclei slices were mounted and photographed
under a microscope.
Imaging experiments
Two weeks after cell transplantation, two animals from
the treatment group, the normal control group, and the
model group were euthanized, and the heart, liver,
spleen, lung, and kidney were subjected to imaging. Each
organ was placed in a dish for in-vivo imaging with a
small animal instrument to observe the distribution of
DiR-labeled cells.
Statistical analysis
The data are shown as the mean ± SD. The groups were
compared using one-way ANOVA with SPSS 17.0 stat-
istical software. P < 0.05 was considered statistically
significant.
Results
Characterization of isolated UC-MSCs
After 3 days in adherent culture, many UC-MSCs sur-
vived. After the medium was changed three times, the
cells were evenly distributed and fusiform, and could be
passaged after confluence. Flow cytometry results
showed a CD29-FITC-positive rate of 99.8 %, a CD44-
FITC-positive rate of 99.7 %, a CD34-FITC-positive rate
of 0 %, and a FITC isotype control rate of 0.014 %. These
results showed that the UC-MSCs of the tree shrews
separated and cultured had MSC surface markers
(Fig. 1).
Quantitative PCR results
Figure 2 shows that, 2 weeks after the injection of pris-
tane and LPS, the IL-17 expression levels in the LPS and
pristane, the pristane only, and the LPS only groups are
higher than in the control group (P < 0.01), and that IL-
17 expression levels in the LPS and pristane group are
significantly higher than in the pristane only and LPS
only groups (P < 0.01 compared with the other three
groups, n = 20). On the contrary, Foxp3 expression levels
in the LPS and pristane, the pristane only, and the LPS
only groups are lower than in the control group (P <
0.01), and the Foxp3 expression levels in the LPS and
pristane group are significantly lower than in the pris-
tane only and LPS only groups (P < 0.01 compared with
the other three groups, n = 20).
ELISA to detect changes in serum IgG and complement
C3 level in tree shrews
The ELISA test results showed that serum IgG levels of
tree shrews injected with pristane and LPS increased
most significantly 3 weeks after injection (P < 0.01 com-
pared with the other three groups, n = 20) (Fig. 3a). The
complement C3 levels increased most significantly in the
pristane and LPS group 3 weeks after injection (P < 0.01
compared with the other three groups, n = 20) (Fig. 3b).
The ELISA OD of standard model tree shrews was >2.8,
more than twice the mean OD value (1.4) of the normal
control group. Quantitative PCR showed that the rela-
tive expression of the IL-17 gene was more than twice
that of the normal control group, while the relative ex-
pression of the Foxp3 gene was less than 0.5 that of the
normal control group. Ten tree shrews were selected
from the pristane and LPS group, divided into a model
control group and a treatment group (each with five ani-
mals). Five normal tree shrews were then randomly se-
lected as the normal control group. In the treatment and
normal control groups, 1 × 106 UC-MSCs from tree
shrews labeled with DiR were injected into the tail vein.
Two weeks after transplantation, the organs of each
group were subjected to imaging and HE staining.
Results of antiphospholipid and antinuclear antibody, and
urine protein
Antiphospholipid test results showed that levels of
serum antiphospholipid IgM (U/ml) were significantly
higher in the model group (P < 0.01 compared with the
other two groups, n = 5). In the normal group, serum
anti-phospholipid IgM was low and antiphospholipid
IgM in the treatment group was significantly decreased
(Fig. 4a). Antinuclear antibody test results showed that
levels of serum antinuclear antibodies in the model
group were significantly higher (P <0.01 in comparison
with the other two groups, n = 5), the normal group
serum anti-nuclear antibody OD value was lower, and
the antinuclear antibody level of the treatment group
was significantly lower (Fig. 4b). Urinary protein results
showed that the mean urinary protein concentration was
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1.812 mg/ml in the model group (n = 5), the mean urin-
ary protein concentration of the normal group was
0.1554 mg/ml, and the mean urinary protein concentra-
tion of the treatment group was 0.462 mg/ml. Urinary
protein concentrations in the model group were signifi-
cantly increased (P < 0.01 in comparison with the other
two groups, n = 5) and the urinary protein was signifi-
cantly decreased in the treatment group (Fig. 4c).
Inflammatory cytokine antibody microarray results
Microarray results showed that 24 inflammatory cyto-
kines increased significantly in the model group vs the
normal group. The upregulated rate is more than 2.0
(Fig. 5a). In the treatment group vs the model group, 17
inflammatory cytokines decreased significantly. The
downregulated rate is less than 0.5 (Fig. 5b). In the
model group, many inflammatory cytokines increased
significantly compared with the normal group; while in
the treatment group, many inflammatory cytokines
decreased significantly compared with the model group.
HE staining of organs and Masson and PAS staining
of kidney
Two weeks after transplantation with tree shrew UC-
MSCs, the HE staining results showed that the lung
(Fig. 6a), liver (Fig. 6d), spleen (Fig. 6g), kidney (Fig. 6j),
and heart (Fig. 6m) of the model control group experi-
enced varying degrees of disease, while those of the nor-
mal control group (Fig. 6b, e, h, k, n) were normal.
Compared with the model control group, the lesions of
the treatment group significantly improved (Fig. 6c, f, i,
l, o). The kidney Masson staining of the model control
group showed renal interstitial fibrosis (Fig. 6p), while
fibrosis was absent in the normal control group (Fig. 6q)
and the treatment group returned to normal (Fig. 6r).
Fibrosis is shown in blue. The kidney PAS staining of
Fig. 1 Characterization of isolated tree shrew UC-MSCs. a Tree shrew UC-MSCs were just adherent. b Tree shrew UC-MSCs covered to be passaged. c
CD29-FITC-positive rate of 99.8 % because UC-MSCs were positive for expression with CD29. d CD44-FITC-positive rate of 99.7 % because UC-MSCs
were positive for expression with CD44. e CD34-FITC is negative because UC-MSCs were negative for expression with CD34. f Isotype control
is negative. The results showed that the UC-MSCs of the tree shrews separated and cultured had UC-MSC surface markers
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the model control group showed red carbohydrate de-
position in the glomeruli (Fig. 6s), but glomerular red
carbohydrate deposition was reduced in the normal con-
trol group (Fig. 6t) and the treatment group (Fig. 6u).
Glycogen dyed red–purple. The percentage of carbohy-
drate area for the three groups was analyzed. The results
are summarized in Table 2 (P < 0.05 compared with the
other two groups, n = 5). Statistical analysis showed that
the percentage of sugar area in the model group was sig-
nificantly higher than in the normal group and the treat-
ment group. There was no significant difference between
the normal group and the treatment group, indicating
that the occurrence of renal lesions improved after treat-
ment, returning to near normal. Ten sections of each
organ in each group and 10 visual fields from each sec-
tion were analyzed. In total, 100 visual fields from each
group were analyzed and the results are summarized
from more than 60 visual fields with similar results. The
similar results are shown in one picture in Fig. 6.
Detection of renal immune complex deposition
The kidney sections were incubated with rabbit anti-
monkey IgG. The results show a large number of im-
mune complexes deposited in the kidneys of the model
group (Fig. 7d, f ); fluorescence substances had been de-
posited, but not in the normal control group (Fig. 7a, c).
The treatment group had fewer renal immune complex
depositions (Fig. 7h, j). These results indicate that renal
immune complex depositions reduced after treatment.
Imaging results
Two weeks after cell transplantation, blood and urine
were collected from the tree shrews in the treatment,
normal control, and model control groups. The animals
were euthanized and the heart, liver, spleen, lung, and
kidney were subjected to imaging. The organs were
placed in a Petri dish, and in-vivo small animal imaging
devices were used to observe the distribution of DiR-
labeled cells (Fig. 8). The labeled cells distributed to the
lung, liver, and spleen in the treatment group (Fig. 8a).
The labeled cells did not distribute in the normal control
(Fig. 8b) and model control (Fig. 8c) groups.
The fluorescence intensity values of various organs are
presented in Table 3.
The fluorescence intensity values of the treatment
group were significantly higher than those of the normal
control group and the model control group, and the
Fig. 2 Gene expression levels in peripheral blood based on quantitative PCR (n = 20). Relative expression levels of the control group were set to
1, and IL-17 expression levels in the LPS and pristane, the pristane only, and the LPS only groups are higher than in the control group (*P < 0.01),
and IL-17 expression levels in the LPS and pristane group are significantly higher than in the pristane only and LPS only groups (*P < 0.01
compared with the other three groups, n = 20). On the contrary, Foxp3 expression levels in the LPS and pristane, the pristane only, and the LPS
only groups are lower than in the control group (*P < 0.01), and Foxp3 expression levels in the LPS and pristane group are significantly lower than
in the pristane only and LPS only groups (*P < 0.01 compared with the other three groups, n = 20)
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difference was statistically significant (P < 0.05 compared
with the other two groups).
Discussion
SLE incidence is believed to be related to genetic causes,
hormonal factors, certain medications, infections, and
other factors. Similar to other autoimmune diseases, the
body continues to produce IgG class autoantibodies to
self-antigens, forming a large number of circulating im-
mune complexes deposited in the glomeruli capillaries
and other tissues to cause glomerulonephritis and whole
body multiple systemic disease. The mechanism is simi-
lar to type III hypersensitivity. Currently, nonspecific im-
munosuppression is used in clinical treatment, and
hematopoietic stem cell transplantation is used to treat a
small number of refractory cases. However, SLE progno-
sis remains to be improved to prevent infection, recur-
rence, kidney failure, and heart and brain damage, and
for other reasons. We hope that the establishment of the
tree shrew SLE model and infusion of UC-MSCs in this
new therapeutic animal study will help to improve treat-
ment efficacy and explore a therapeutic mechanism.
Under certain conditions, MSCs can differentiate into
a variety of tissue cells, such as osteoblasts, chondro-
cytes, tendon cells, and adipocytes. However, they can
also differentiate across the mesoderm to the endoderm
and neural ectoderm (such as the liver, bile duct epithe-
lium, lung, intestine, skin epithelium, and neuronal and
Fig. 3 ELISA was used to detect changes in the tree shrew serum IgG and complement C3 levels at 1, 2, and 3 weeks after injection (n = 20)
(*P < 0.01 compared with the other groups 3 weeks after injection). a Serum IgG levels of tree shrews injected with pristane and LPS increased
most significantly 3 weeks after injection (*P < 0.01 compared with the other three groups, n = 20). b Complement C3 levels increased most
significantly in the pristane and LPS group 3 weeks after injection (*P < 0.01 compared with the other three groups, n = 20). LPS lipopolysaccharide, OD
optical density, W week
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glial cells) [11]. Pan et al. [12] have reported using BM-
MSC transplantation to treat diabetic nephropathy in
tree shrews. However, UC-MSCs are readily available
and not rejected after replantation; these cells show a
strong ability to self-replicate, are easily separated and
amplified in vitro, and should be widely used in tissue
engineering, cell transplantation, and gene therapy. UC-
MSCs are therefore an ideal seed cell. UC-MSCs have
immunosuppressive effects. Application of UC-MSC
treatment for SLE involves allogeneic cell transplant-
ation. By restoring the balance of autoreactive T cells in
SLE patients, UC-MSCs exert immunosuppressive ef-
fects by reaching immune homeostasis again and achieve
a therapeutic effect.
The role of CD4+CD25+ T cells is not fully under-
stood [13]. The possible mechanisms are secretion of
TGF-β and/or IL-10 or induction of other cells to se-
crete other inhibitory cytokines. With high cell surface
expression of TGF-β, CD4+CD25+ T cells bind the
TGF-β receptor and inhibit the autoreactive T cells and
B cells. CD4+CD25+ T cells in the body account for
10 % of total CD4+ T cells. The number and activity of
CD4+CD25+ T cells meet the need to inhibit autoreac-
tive T-lymphocyte and B-lymphocyte activation, as well
as the proliferation and maintenance of autoimmune
balance. In individuals susceptible to SLE, environmen-
tal factors, genetic abnormalities, and other factors
affect the production of CD4+CD25+ T cells in the thy-
mus, which can lead to SLE [14]. Previous studies
showed that the level of CD4+CD25+ T cells was signifi-
cantly lower in SLE patients than in healthy controls,
irrespective of the status (active or inactive) [15].
Because the numbers of CD4+CD25+ T cells were re-
duced, which results in immune suppression, the acti-
vation of T-helper cells was enhanced, the expression
of B-cell activating factor increased, and B-lymphocyte
hyperthyroidism was induced to produce a variety of
autoantibodies, which led to a series of immune system
interaction disorders that resulted in multiple organ
damage. We used quantitative PCR to detect the Foxp3
gene because its change indirectly represents the
change in CD4+CD25+ T cells in peripheral blood. Our
results showed in that in the model tree shrew, the ex-
pression of the Foxp3 gene decreased. The relative
expression of the Foxp3 gene was less than 0.5 of that
in the normal control group (P < 0.01). The decrease in
Foxp3 gene expression is enough to have biological im-
pact on CD4+CD25+ T cells. This result indirectly
shows that in the SLE model CD4+CD25+ T cells are
significantly lower than in healthy controls. According
to the literature, CD4+CD25+ T cells are a subset of
regulatory T cells that mainly originate from the thy-
mus. Their main function is related to the inhibition of
the immune response of autoreactive T cells, the inhib-
ition of conventional T-cell activation, and the promo-
tion of the secretion of some suppression cytokines.
The cells play an important role in the maintenance of
a stable internal environment and tumor immune sur-
veillance, and induce transplantation tolerance and
Fig. 4 Antiphospholipid and antinuclear antibody and urine protein.
a ELISA results of antiphospholipid showed that levels of serum
antiphospholipid IgM (U/ml) were significantly higher in the model
group (*P < 0.01 compared with the other two groups, n = 5). b
ELISA results of antinuclear antibody showed that levels of serum
antinuclear antibodies in the model group were significantly higher
(*P < 0.01 in comparison with the other two groups, n = 5). c Urine
protein quantitation results in the model group were significantly
increased (*P < 0.01 in comparison with the other two groups) and
the urinary protein was significantly decreased in the treatment
group (n = 5). OD optical density
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autoimmune diseases. SLE patients with increased
Th17 cells in the peripheral blood show a decreased
population of CD4+CD25+ T cells, which increases per-
ipheral IL-17 gene expression and decreases Foxp3 gene
expression.
The literature indicates the use of LPS [16–18] and
pristane [19–21] by intraperitoneal injection to induce
SLE in mouse studies, but the tree shrew SLE model has
not been studied. We therefore used 80 tree shrews, di-
vided into four groups of 20. Studies have shown that
pristane and LPS injection in tree shrews induces SLE-
related changes, including an increase in the peripheral
IL-17 gene [22], reduction in the Foxp3 gene, elevated
serum IgG and C3, multiorgan lesions, and immune
complex deposition in kidney sections. We divided 10
model tree shrews into five model control groups and
five treatment groups, and the model success criterion
was defined as an ELISA OD value of standard model
tree shrews >2.8, more than twice the mean OD value
(1.4) of the normal control group. Quantitative PCR
showed that the relative expression of the IL-17 gene
was more than twice that of the normal control group,
while that of the Foxp3 gene was less than 0.5 that of
the normal control group. DiR-labeled cells (1 × 106
cells) were transplanted into each tree shrew in the
treatment and the normal control groups; 2 weeks later,
three groups of tree shrews were used to detect serum
antiphospholipid and antinuclear antibodies simultan-
eously with an inflammatory cytokine antibody micro-
array. From three groups of tree shrews, morning urine
was analyzed for urine protein concentration, and the
heart, liver, spleen, lungs, and kidneys were imaged. The
imaging results showed that labeled cells were distrib-
uted in the lung, liver, and spleen of tree shrews in the
treatment group, and fluorescence intensity values of the
normal and model control groups of all organs were
lower than in the treatment group. Labeled UC-MSCs
from tree shrews mainly were located in the damaged
organs. Because organ damage was absent in the normal
control group, the detected fluorescence intensity values
Fig. 5 Inflammatory cytokine antibody microarray results. a Model group vs normal group; 24 inflammatory cytokines increased significantly.
The upregulated rate is more than 2.0. b Treatment group vs model group; 17 inflammatory cytokines decreased significantly. The downregulated rate
is less than 0.5
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Fig. 6 HE staining and renal Masson and PAS staining for three groups of tree shrew organs (400× magnification). a–o HE staining: a model
control group showing slightly thickened alveolar septa and some alveolar atrophy, alveolar compensatory expansion, and bulla formation
(arrow); b normal control group with normal lung; c treatment group without bulla formation. d model control group with diffuse hepatic cell
necrosis formation (arrow) and eosinophilic bodies, granulocyte infiltration, and a large amount of liver cell degeneration; e normal control group
with normal liver; f treatment group without granulocyte infiltration; g model control group showing a large amount of granulocyte infiltration in
spleen red pulp (arrow); h normal control group with normal spleen; i treatment group without granulocyte infiltration; j model control group
with part of the renal cyst and renal tubular cavity showing a large lightly stained mucus-like substance (arrow); k normal control group with
normal kidney; l treatment group without mucus-like substance; m model control group with minor bleeding and a small amount of cardiac
hypertrophy (arrow); n normal control group with normal heart; and o treatment group returned to normal without cardiac hypertrophy. p–r
Kidney Masson staining: p model control group with renal interstitial fibrosis (arrow; fibrosis in blue); q normal control group with normal kidney; and r
treatment group with less renal interstitial fibrosis. s–u Kidney PAS staining: s model control group with glycogen deposition in glomeruli
(arrow; glycogen dyed red–purple); t normal control group with less glycogen deposition; and u treatment group with less glycogen deposition
(Color figure online)
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were lower than those in the treatment group, and most
values were lower by an order of magnitude. Labeled
cells did not transplant in the model control group; thus,
the detected fluorescence intensity values were lower
than in the treatment group, and most values were
lower by an order of magnitude. Serum antiphospholi-
pid and antinuclear antibodies results showed that in
the model group antiphospholipid and antinuclear anti-
bodies increased significantly. In the treatment group,
antiphospholipid and antinuclear antibodies decreased
significantly. This result indicates that UC-MSC ther-
apy is effective in the SLE model. Urine protein quanti-
tation results also showed that UC-MSC therapy can
effectively decrease urine protein concentrations in the
SLE model.
In summary, we reviewed a large body of domestic
and foreign literature and established a tree shrew SLE
model. The pathological and serological results and gen-
omics showed that the SLE tree shrew model was estab-
lished successfully. After initial UC-MSC therapy, we
found labeled cells in the heart, liver, spleen, lung, and
kidney of tree shrews in the treatment group. The region
of interest (ROI) fluorescence values were higher than in
the control tree shrews, and most of these ROI values
were larger by one order of magnitude. These findings
provide a theoretical and experimental basis for using
UC-MSCs to treat SLE.
Conclusions
Ten modeled tree shrews from the pristine and LPS in-
jection groups were grouped into the treatment group
and the model control group, with five animals per
group. Five normal tree shrews were selected as the nor-
mal control group. DiR-labeled UC-MSCs (1 × 106 cells)
were transplanted into animals of the treatment and
normal control groups. Two weeks after transplantation,
the heart, liver, spleen, lung, and kidney of the three
groups were stained with HE and kidney Masson and
PAS stain, and were imaged. The results revealed obvi-
ous pathological changes in the model group, while the
treatment group returned to normal levels. The imaging
results showed that labeled cells were mainly localized in
the lungs, liver, and spleen in the treatment group, and
Table 2 Comparison of sugar area percentage revealed by renal







Sugar area percentage 2.45 ± 1.08 4.48 ± 0.74 18.55 ± 3.48
*P < 0.05 compared with the other two groups (n = 5)
PAS periodic acid–Schiff
Fig. 7 Detection of renal immune complex deposition. a–c Normal control group: the kidney has no immune complex deposition (no red
fluorescence). d–f Model control group: the kidney has plenty of immune complex deposition (red fluorescence shows immune complex
deposition). g–i Treatment group: the kidney has less immune complex deposition (less red fluorescence). a, d, g Red fluorescence channel. b, e, h
Blue fluorescence channel, DAPI staining. c, f, i Merged red and blue fluorescence channels (Color figure online)
Ruan et al. Stem Cell Research & Therapy  (2016) 7:121 Page 11 of 14
Fig. 8 Imaging of tree shrew organs. a Transplanted labeled cells in the treatment group: labeled cells distributed to the lung, liver, and spleen.
b Transplanted labeled cells in the normal control group: labeled cells did not distribute. c Untreated model control group: labeled cells were not
detected. The fluorescence intensity values of the treatment group were significantly higher than those of the normal control group and the
model control group
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the ROI value of organs of the treatment group was
significantly higher than in the normal control group
and in the model control group. This difference was
statistically significant (P < 0.05). This finding proved
that UC-MSCs have a therapeutic effect in the tree
shrew SLE model. In the future, we can use UC-MSCs
to treat human SLE in clinical trials.
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